98%
921
2 minutes
20
In the United States, ∼30,000 units of red blood cells (RBCs) are transfused daily to patient recipients. These RBCs are stored in one of multiple variations of media known as additive solutions, all of which contain glucose at concentrations well above physiological levels. Recently, strategies for storage of the RBCs in normoglycemic versions of the additive solutions whose glucose levels are maintained with periodic boluses of glucose were developed, resulting in benefits to the stored RBCs. Here, we describe a system capable of semiautonomous, Wi-Fi-enabled control of glucose delivery using a microperistaltic pump for maintenance of physiological concentrations of glucose in a closed RBC storage system. The RBCs stored in these normoglycemic conditions demonstrated reduced lysis and reduced hemoglobin glycation in comparison to those of the currently used hyperglycemic additive solutions. Furthermore, a novel single cell technique using pressure-induced conductivity mapping showed an improved Young's modulus for those RBCs stored in normoglycemic solutions. These quantitative measurements of the RBCs' chemical and physical properties coincide with improvements in cell functionality. Specifically, determinations of RBC-derived ATP using a 3D-printed microfluidic device show an increased release of ATP for RBCs stored in normoglycemic solutions in comparison to hyperglycemic storage, even for cells that were 2 weeks past a storage expiration of 42 days.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12371595 | PMC |
http://dx.doi.org/10.1021/acsmeasuresciau.5c00032 | DOI Listing |
Front Cell Dev Biol
August 2025
Department of Transfusion, Wuhan Fourth Hospital, Wuhan, Hubei, China.
Background: Massive hemorrhage is a leading cause of mortality among trauma patients. To date, whole blood (WB) remains the preferred resuscitation fluid on the battlefield and in pre-hospital emergency care. However, components of WB inevitably undergo storage-related damage, and differences in the duration of storage may lead to varying clinical outcomes after transfusion.
View Article and Find Full Text PDFVox Sang
August 2025
Academy of Military Medical Science, Beijing, People's Republic of China.
Background And Objectives: This study aims to develop a novel platform combining machine learning and microscope images for personalized assessment of red blood cell (RBC) storage lesions. RBCs undergo storage lesions, which adversely affect transfusion outcomes. Currently, there is no individualized assessment method for RBC aging applicable in clinical practice.
View Article and Find Full Text PDFACS Meas Sci Au
August 2025
Departments of Biomedical Engineering and Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, Michigan 48824, United States.
In the United States, ∼30,000 units of red blood cells (RBCs) are transfused daily to patient recipients. These RBCs are stored in one of multiple variations of media known as additive solutions, all of which contain glucose at concentrations well above physiological levels. Recently, strategies for storage of the RBCs in normoglycemic versions of the additive solutions whose glucose levels are maintained with periodic boluses of glucose were developed, resulting in benefits to the stored RBCs.
View Article and Find Full Text PDFVox Sang
August 2025
NHS Blood and Transplant, Bristol Institute for Transfusion Sciences, Bristol, UK.
Background And Objectives: Cultured red blood cells (cRBCs) have many potential applications, including in diagnostics, as drug delivery carriers or for specialized clinical use. However, cRBCs are immature reticulocytes that do not store well. After 10 days of cold storage in saline, adenine, glucose, mannitol (SAG-M), cRBCs show around 8% haemolysis compared to <0.
View Article and Find Full Text PDFVox Sang
August 2025
Product and Process Development, Canadian Blood Services, Vancouver, British Columbia, Canada.
Background And Objectives: Due to toxicity concerns, di(2-ethylhexyl) phthalate (DEHP)-the most used plasticizer in polyvinyl chloride (PVC) whole blood (WB) collection and processing bag sets-will be effectively prohibited in medical devices in Europe from 2030. Removal of DEHP will primarily impact the in vitro quality of red blood cell (RBC) concentrates (RCCs) and DEHP-free sets with alternate additive solutions (ASs) that better preserve RBCs in the absence of DEHP are being developed. This study compared the in vitro quality of RCCs from di (2-ethylhexyl) terephthalate (DEHT)/phosphate-adenine-glucose-guanosine-saline-mannitol (PAGGSM) and DEHP/saline-adenine-glucose-mannitol (SAGM) sets.
View Article and Find Full Text PDF